DE69227088T2 - Verwendung von 1-(aminoalkyl)-3-Quinoxalin-2-on Derivaten zur Herstellung von neuroprotektiven Mitteln - Google Patents
Verwendung von 1-(aminoalkyl)-3-Quinoxalin-2-on Derivaten zur Herstellung von neuroprotektiven MittelnInfo
- Publication number
- DE69227088T2 DE69227088T2 DE69227088T DE69227088T DE69227088T2 DE 69227088 T2 DE69227088 T2 DE 69227088T2 DE 69227088 T DE69227088 T DE 69227088T DE 69227088 T DE69227088 T DE 69227088T DE 69227088 T2 DE69227088 T2 DE 69227088T2
- Authority
- DE
- Germany
- Prior art keywords
- quinoxalin
- aminoalkyl
- derivatives
- production
- neuroprotective agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 125000004103 aminoalkyl group Chemical group 0.000 title 1
- 239000004090 neuroprotective agent Substances 0.000 title 1
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 102000018899 Glutamate Receptors Human genes 0.000 abstract 1
- 108010027915 Glutamate Receptors Proteins 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 206010029350 Neurotoxicity Diseases 0.000 abstract 1
- 206010044221 Toxic encephalopathy Diseases 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- -1 methoxy, ethoxy, hydroxy Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000007135 neurotoxicity Effects 0.000 abstract 1
- 231100000228 neurotoxicity Toxicity 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP91119501 | 1991-11-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69227088D1 DE69227088D1 (de) | 1998-10-29 |
| DE69227088T2 true DE69227088T2 (de) | 1999-06-02 |
Family
ID=8207340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69227088T Expired - Fee Related DE69227088T2 (de) | 1991-11-15 | 1992-11-09 | Verwendung von 1-(aminoalkyl)-3-Quinoxalin-2-on Derivaten zur Herstellung von neuroprotektiven Mitteln |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US5563140A (de) |
| JP (1) | JPH06239747A (de) |
| AT (1) | ATE171374T1 (de) |
| DE (1) | DE69227088T2 (de) |
| ES (1) | ES2123546T3 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0784973B1 (de) * | 1995-10-10 | 2002-02-06 | Pfizer Inc. | Quinoxalin-Derivate zur Behandlung von Tinnitus |
| EP1009316B1 (de) * | 1997-08-07 | 2013-10-09 | Natan Bauman | Vorrichtung und methode zur gehörstimulation |
| AT408837B (de) * | 1998-06-19 | 2002-03-25 | Phafag Ag | Verwendung von caroverin und/oder caroverin. hydrochlorid zur herstellung von als antioxidantien wirkenden zusammensetzungen und/oder von neuroregenerativen zusammensetzungen |
| US20030045541A1 (en) * | 2001-07-23 | 2003-03-06 | Christopher Bruckner | GABA-Receptor modulators with NMDA-Antagonistic activity |
| DE60326731D1 (de) * | 2002-07-31 | 2009-04-30 | Phafag Ag | Arzneizubereitung und deren anwendung zur behandlu |
| US7751580B2 (en) * | 2002-09-10 | 2010-07-06 | Auditory Licensing Company, Llc | Open ear hearing aid system |
| US7421086B2 (en) | 2002-09-10 | 2008-09-02 | Vivatone Hearing Systems, Llc | Hearing aid system |
| US20050078843A1 (en) * | 2003-02-05 | 2005-04-14 | Natan Bauman | Hearing aid system |
| EP1861161A4 (de) * | 2005-01-24 | 2012-05-16 | Neurosystec Corp | Vorrichtung und verfahren zur abgabe therapeutischer und/oder anderer mittel im innenohr und an andere gewebe |
| CN101163481A (zh) * | 2005-03-04 | 2008-04-16 | 纽罗赛斯特克公司 | 改进的加环利定制剂 |
| WO2007012064A2 (en) * | 2005-07-20 | 2007-01-25 | Cypress Bioscience, Inc. | Prevention and treatment of hearing disorders |
| US8267905B2 (en) | 2006-05-01 | 2012-09-18 | Neurosystec Corporation | Apparatus and method for delivery of therapeutic and other types of agents |
| US7803148B2 (en) * | 2006-06-09 | 2010-09-28 | Neurosystec Corporation | Flow-induced delivery from a drug mass |
| JP2009544355A (ja) * | 2006-07-20 | 2009-12-17 | ニューロシステック コーポレイション | 眼科薬物送達のためのデバイス、システム、および方法 |
| US20080145439A1 (en) * | 2006-07-31 | 2008-06-19 | Neurosystec Corporation | Nanoparticle drug formulations |
| US20080065002A1 (en) * | 2006-09-07 | 2008-03-13 | Neurosystec Corporation | Catheter for Localized Drug Delivery and/or Electrical Stimulation |
| KR101117129B1 (ko) | 2009-09-14 | 2012-02-24 | 한국화학연구원 | 신규한 퀴녹살린 유도체 및 이를 포함하는 줄기세포의 신경세포로의 분화유도용 조성물 |
| EP2522350B1 (de) | 2011-05-12 | 2013-07-31 | Immunopharm AG | Verwendung der Wirkstoffkombination aus einem 1-Diethylaminoethyl-3-Chinoxalin-2-on Derivat und einem Oxysterol zur Durchbrechung von Resistenzen bei der Behandlung von Krebs und zur Erhöhung der Immunleistungsfähigkeit bei Krebs, bakteriellen und viralen Erkrankungen, Autoimmunerkrankungen, erhöhter Stress- und Umweltbelastung |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE228204C (de) * | ||||
| DE3047811A1 (de) * | 1979-12-28 | 1981-10-29 | Medichemie AG, 4107 Ettingen | "pharmazeutische verwendung von caroverin und/oder caroverinsalzen sowie caroverinsalze mit xanthinderivat-saeureresten und nicotinsaeurerest |
| US4975430A (en) * | 1989-06-16 | 1990-12-04 | The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University | CNQX and its analogs as therapeutics for degenerative neural diseases |
| US5037848A (en) * | 1989-08-25 | 1991-08-06 | Washington University | Aryl-cycloalkyl-alkanolamines for treatment of epilepsy |
-
1992
- 1992-11-09 ES ES92810863T patent/ES2123546T3/es not_active Expired - Lifetime
- 1992-11-09 AT AT92810863T patent/ATE171374T1/de not_active IP Right Cessation
- 1992-11-09 DE DE69227088T patent/DE69227088T2/de not_active Expired - Fee Related
- 1992-11-16 US US07/975,328 patent/US5563140A/en not_active Expired - Lifetime
- 1992-11-16 JP JP4329024A patent/JPH06239747A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US5563140A (en) | 1996-10-08 |
| ATE171374T1 (de) | 1998-10-15 |
| JPH06239747A (ja) | 1994-08-30 |
| DE69227088D1 (de) | 1998-10-29 |
| ES2123546T3 (es) | 1999-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69227088D1 (de) | Verwendung von 1-(aminoalkyl)-3-Quinoxalin-2-on Derivaten zur Herstellung von neuroprotektiven Mitteln | |
| MY119150A (en) | Azetidine derivatives, their preparation and medicaments containing them | |
| FI891548A0 (fi) | Administrering av monoaminakridiner i kolinergiska bristtillstaond av nervceller. | |
| MY117896A (en) | Quinazoline derivatives | |
| IL124537A0 (en) | Naphthyl-substituted benzimidazole derivatives and pharmaceutical compositions containing the same | |
| NO942953D0 (no) | 11-benzaldoksimestradienderivater, fremgangsmåte for deres fremstilling smat legemddel inneholdende slike | |
| ES2048109A1 (es) | Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol. | |
| DE3462504D1 (de) | Indole-3-carboxamide derivatives | |
| NO951484D0 (no) | Kinolon- og akridinon-derivater for behandling av urininkontinens | |
| GB2311780B (en) | Pharmaceutical Piperazine Compounds | |
| GR3020292T3 (en) | Use of 2-iminothiazolidin-4-one derivatives as new medicaments | |
| GR3017813T3 (en) | 6,7-disubstituted-2-aminotetralines active as immunomodulators and pharmaceutical compositions containing same. | |
| ATE341329T1 (de) | Arzneimittel zur behandlung von neuropathien | |
| IL115085A (en) | Piperazine bicyclic carboxamide derivatives their preparation and pharmaceutical compositions containing them | |
| ZA934110B (en) | Diacylglycerol nicotinates, process fot their preparation and the pharmaceutical compositions which contain them | |
| AU4583489A (en) | New indole derivatives, process for preparing them and pharmaceutical compositions containing them | |
| DE3862660D1 (de) | 2,3-dihydro-2-oxo-3-benzofuranyl-essigsaeurederivate und diese enthaltende arzneimittel. | |
| GR3024388T3 (en) | 2-phenyl-and 2-thienyl-(2)-piperidine derivatives having neuroprotective properties | |
| AU7532787A (en) | New derivatives of 2,6-piperazinedione, their preparation process and the pharmaceutical compositions containing them | |
| CS548987A2 (en) | Process for preparing new tetracycline derivatives of indole | |
| AU657423B2 (en) | Novel piperidine derivatives and process for preparation thereof | |
| ES2056025A1 (es) | Nuevos derivados de indol. | |
| CA2388176A1 (en) | Therapeutic agent for eating disorders | |
| ES2006336A6 (es) | Procedimiento de preparacion de nuevas acetamidas derivadas de la 2,3-dihidro-3-fenil-2-benzofuranona. | |
| DE69308865D1 (de) | Ureidoacetamid-derivate,irhe herstellung und sie enthaltende medikamente |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: PHAFAG AG, SCHAANWALD, LI |
|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |